Under the terms of the agreement, Savira will receive a non-disclosed one-time payment in return for a non-exclusive, world-wide license to a part of Savira’s influenza polymerase patent rights. The agreement relates to a previous collaboration between Roche and Savira, which was terminated recently.
Savira pharmaceuticals GmbH – based in Vienna, Austria – is focusing on the design of novel, innovative influenza therapeutics using a rational, structure-based drug development approach. Savira follows the biotech business model, turning capital and public grants into the preclinical and clinical development of a portfolio of anti-influenza drug candidates. Savira thus strives to create a sustainable pipeline, generate value for shareholders, improve quality of life for people suffering from influenza, and add to the arsenal of antivirals thus improving influenza pandemic preparedness.